Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2 Multi-Center, Randomized, Double Masked, Placebo Controlled Study to Assess the Safety and Efficacy of ST-100 Ophthalmic Solution in Subjects Diagnosed With Dry Eye Disease

Next Previous
Trial Profile

A Phase 2 Multi-Center, Randomized, Double Masked, Placebo Controlled Study to Assess the Safety and Efficacy of ST-100 Ophthalmic Solution in Subjects Diagnosed With Dry Eye Disease

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 15 Mar 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Vezocolmitide (Primary)
  • Indications Dry eyes
  • Focus First in man; Therapeutic Use
  • Sponsors Stuart Therapeutics

Most Recent Events

  • 18 Jul 2022 According to a Stuart Therapeutics media release, the company Stuart provided the FDA with the results of the ST-100 Phase 2 clinical trial, completed late last year, and asked for the agency's guidance relating to the company's proposed next steps.
  • 04 Feb 2022 Status changed from active, no longer recruiting to completed.
  • 03 Jan 2022 Primary endpoint has been met. (Schirmers Test Responder Rate), according to a Stuart Therapeutics media release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top